{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:19:43Z","timestamp":1777389583711,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cmi.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T02:30:59Z","timestamp":1653013859000},"page":"1367-1374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Translational in\u00a0vitro and in\u00a0vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia"],"prefix":"10.1016","volume":"28","author":[{"given":"Vincent","family":"Aranzana-Climent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diarmaid","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Tomczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata","family":"Urbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Zabicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Vingsbo Lundberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven N.","family":"Hobbie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.05.003_bib1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.003_bib3","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","article-title":"Critical analysis of antibacterial agents in clinical development","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2022.05.003_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/d41573-021-00074-y","article-title":"ENABLE: an engine for European antibacterial drug discovery and development","volume":"20","author":"Olliver","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cmi.2022.05.003_bib5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/jac\/dky546","article-title":"In\u00a0vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"74","author":"Juhas","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.05.003_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.diagmicrobio.2017.03.006","article-title":"In vitro apramycin activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"88","author":"Kang","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.003_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/mdr.2019.0075","article-title":"Dissemination of international clone II Acinetobacter baumannii strains coproducing OXA-23 carbapenemase and 16S rRNA methylase ArmA in Athens, Greece","volume":"26","author":"Nafplioti","year":"2020","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.cmi.2022.05.003_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.05.003_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12941-021-00468-1","article-title":"Antimicrobial susceptibility patterns of respiratory Gram-negative bacterial isolates from COVID-19 patients in Switzerland","volume":"20","author":"Gysin","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.cmi.2022.05.003_bib10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1089\/mdr.2017.0101","article-title":"Evaluation of aminoglycoside and carbapenem resistance in a collection of drug-resistant Pseudomonas aeruginosa clinical isolates","volume":"24","author":"Holbrook","year":"2018","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.cmi.2022.05.003_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.diagmicrobio.2016.09.002","article-title":"Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae","volume":"86","author":"Smith","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.003_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3389\/fmicb.2020.00425","article-title":"In vitro activity of apramycin against carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates","volume":"11","author":"Hao","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2022.05.003_bib13","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.3389\/fmicb.2017.02275","article-title":"In vitro activity of neomycin, streptomycin, paromomycin and apramycin against carbapenem-resistant Enterobacteriaceae clinical strains","volume":"8","author":"Hu","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2022.05.003_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01374-19","article-title":"Synergistic combinations and repurposed antibiotics active against the pandrug-resistant Klebsiella pneumoniae Nevada strain","volume":"63","author":"Brennan-Krohn","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.05.003_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jgar.2020.12.006","article-title":"Vertical and horizontal dissemination of an IncC plasmid harbouring rmtB 16S rRNA methylase gene, conferring resistance to plazomicin, among invasive ST258 and ST16 KPC-producing Klebsiella pneumoniae","volume":"24","author":"Roch","year":"2021","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2022.05.003_bib16","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/cpt.2104","article-title":"Model-informed drug development for antimicrobials: translational PK and PKPD modelling to predict an efficacious human dose for apramycin","volume":"109","author":"Sou","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2022.05.003_bib17","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cmi.2020.12.004","article-title":"Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice","volume":"27","author":"Becker","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.05.003_bib18","doi-asserted-by":"crossref","first-page":"103652","DOI":"10.1016\/j.ebiom.2021.103652","article-title":"Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"73","author":"Becker","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cmi.2022.05.003_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02585-17","article-title":"Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the murine neutropenic thigh model","volume":"62","author":"Kang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.05.003_bib20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cpt.2182","article-title":"Pivotal role of translation in anti-infective development","volume":"109","author":"Friberg","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2022.05.003_bib21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/cpt.2198","article-title":"Model-informed drug development for anti-infectives: state of the art and future","volume":"109","author":"Rayner","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2022.05.003_bib22","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1093\/jac\/dky239","article-title":"Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients","volume":"73","author":"Boisson","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.05.003_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.cmi.2022.05.003_bib24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","article-title":"Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling","volume":"43","author":"Dosne","year":"2016","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.cmi.2022.05.003_bib25","author":"Karlsson"},{"key":"10.1016\/j.cmi.2022.05.003_bib27","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1128\/AAC.36.9.1951","article-title":"Adaptive resistance following single doses of gentamicin in a dynamic in\u00a0vitro model","volume":"36","author":"Barclay","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.05.003_bib28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/00003495-200161060-00001","article-title":"Aminoglycoside adaptive resistance: importance for effective dosage regimens","volume":"61","author":"Barclay","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2022.05.003_bib30","author":"EUCAST"},{"key":"10.1016\/j.cmi.2022.05.003_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02553-16","article-title":"Population pharmacokinetic modeling as a tool to characterize the decrease in ciprofloxacin free interstitial levels caused by Pseudomonas aeruginosa biofilm lung infection in Wistar rats","volume":"61","author":"Torres","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22002592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22002592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:31:56Z","timestamp":1761118316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22002592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1198743X22002592"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.05.003","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational in\u00a0vitro and in\u00a0vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}